Celularity Inc. reports developments in regenerative and cellular medicine, including longevity-focused programs, placental-derived cell therapies and commercial regenerative medicine products such as Biovance and Biovance 3L. Company news also covers clinical and coverage-related updates, operating and financial results, capital-structure actions and governance matters.
Recurring corporate updates include periodic-reporting status, Nasdaq compliance, tax-credit monetization, material agreements and shareholder matters. The company's disclosures also reference its common stock and warrants trading on Nasdaq under CELU and CELUW.
Celularity (Nasdaq: CELU) signed an exclusive manufacturing agreement with Vesalius Longevity Labs to establish a U.S. platform for Peptual peptide ingredients.
Celularity will handle final-stage manufacturing at its Florham Park, New Jersey facility, including downstream purification, processing and analytical testing of supplier-provided bulk peptides. The parties intend to develop processes meeting current good manufacturing practice requirements, with documented sourcing and lot-level traceability.
Supply to appropriately licensed U.S. compounding pharmacies is conditional on the FDA adding covered peptide substances and forms to its permitted bulk-drug list following advisory committee consideration. Signing the agreement or completing development does not itself authorize commercial release, distribution or use.
Celularity (Nasdaq: CELU) has regained compliance with Nasdaq’s periodic financial reporting requirement, closing its previously disclosed reporting deficiency matter.
The determination followed the company’s October 20, 2026 filing of its quarterly report for the period ended June 30, 2026. Nasdaq had already confirmed compliance with its minimum bid price and minimum market value requirements on September 11, 2026. All three previously disclosed deficiency matters are now closed. Celularity has begun a process to overhaul its finance organization, and the board is working with CEO Robert Hariri to identify experienced finance professionals.
Celularity (CELU) highlighted progress at Fontaine Vitale, a regenerative medicine and wellness center expected to open in the first quarter of 2027.
Genting Berhad and its Indonesian partners are developing the center in Bali’s Sanur Special Economic Zone, with collaboration and input from Celularity. The facility is expected to offer placenta-derived allogeneic stem cell therapy, which uses donor cells, using Celularity’s technology and products manufactured in New Jersey. Celularity expects to supply its placenta-derived products, subject to final commercial arrangements, applicable regulatory authorizations, treatment protocols and market conditions.
Celularity (CELU) announced that Viome founder and CEO Naveen Jain will join its board of directors.
His appointment will take effect after completion of the applicable Rule 14f-1 information statement process. The newly constituted board includes Robert Hariri, Peter Diamandis and Philip Barach. Celularity expects to announce a fifth director shortly.
Celularity (CELU) closed a private placement raising over $10 million in gross cash proceeds on September 24, 2026.
The initial closing is part of a recapitalization contemplating up to $25 million in new cash, including proceeds already received, and restructuring approximately $3 million of existing debt. Gross proceeds precede transaction expenses and debt repayment. The senior secured convertible notes mature 24 months after issuance and bear 10% annual interest, compounded annually. Initial-closing notes are initially convertible at $1.50 per Class A share. Five-year warrants are initially exercisable at $1.50 and cover 11 shares for every 20 shares initially issuable on conversion.
Monthly cash burn has fallen by more than $1 million. Celularity expects positive monthly operating cash flow by the end of the first quarter of 2027. Management estimates that existing investigational cenplacel-L inventory represents approximately $40 million in potential sales. Additional financing closings remain conditional and are not assured.
Celularity (Nasdaq: CELU) and MuseCell Innovations announced a U.S.-based manufacturing collaboration under which Celularity will establish production of Dezawa MuseCells (DMCs) at its 147,215-square-foot Florham Park, New Jersey facility. The initial program will set up manufacturing capability for MCI-authenticated DMC preparations from qualified perinatal, bone marrow and adipose sources using the licensed Dezawa Method and MCI’s product specifications.
The collaboration also covers DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome, each with dedicated processes, analytical characterization and release criteria. Following the initial project, the parties intend to expand to additional products and programs. Based on current market conditions and its projections, MCI believes the expanded relationship could result in more than $300 million in aggregate purchases from Celularity over five years and is anticipated to generate more than 200 high-tech jobs at the Florham Park site while expanding MCI’s U.S. manufacturing network and preserving its quality, traceability and authentication framework.
Celularity (Nasdaq: CELU) reported that on August 21, 2026 it received a Nasdaq Listing Qualifications notice stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-Qs for quarters ended March 31 and June 30, 2026.
According to Celularity, Nasdaq has requested a compliance plan by September 4, 2026, and any exception would run no later than November 16, 2026. The notice has no immediate effect on the listing or trading of Celularity’s common stock, which continues on the Nasdaq Capital Market under the symbol CELU. The company is working to complete and file both quarterly reports as soon as practicable.
Celularity (Nasdaq: CELU) and Fountain Life announced that cenplacel-L, a placental-derived allogeneic investigational cell therapy, will be available for physician-directed investigational use in Florida under new regenerative medicine statutes effective July 1, 2025.
The partnership leverages Celularity’s FDA-registered, GMP-compliant facility and Fountain Life’s preventive, longevity-focused care model.
Celularity (Nasdaq: CELU) released a CEO letter outlining a sharper focus on placental-derived cellular therapies for longevity and age-related disease.
The company out-licensed its biomaterials business to NexGel for up to $30 million, eliminated nearly $13 million of recorded liabilities, highlighted growing physician demand for cenplacel-L, emphasized early commercial efforts in Florida with Fountain Life, and announced Rick Gonzalez as Chief Commercial Officer while acknowledging residual debt and capital constraints.
Celularity (Nasdaq: CELU) appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. He will lead global commercialization of cenplacel-L, the Lifebank cellular banking platform and the broader regenerative medicine portfolio, reporting to CEO Robert J. Hariri.
Gonzalez brings 20+ years of biotech and medtech leadership, including roles at Alume Biosciences, Navidea Biopharmaceuticals and Spectrum Pharmaceuticals, where he previously helped drive significant revenue expansion. Celularity cites growing physician demand in permissive markets for cenplacel-L and ongoing 2025 Lifebank sales as drivers to strengthen commercial capabilities.